Protocols
CHIMAGEN-CMG1A46-US01 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First in Human, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Triple-Specific T-Cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-Cell Hematologic Malignancies
NU-20H09-NHL Phase II OPEN TO ACCRUAL
Phase II, Single-Arm, Open-Label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-cell Non-Hodgkins Lymphoma
NURIX-NX-5948-301 Phase I OPEN TO ACCRUAL
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
TENEOBIO-TENEOTWO-TNB486-001 Phase I OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma